Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
123.29
+4.16 (3.49%)
At close: Nov 20, 2024, 4:00 PM
124.01
+0.72 (0.58%)
Pre-market: Nov 21, 2024, 4:13 AM EST
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
The 23 analysts with 12-month price forecasts for NBIX stock have an average target of 163.91, with a low estimate of 114 and a high estimate of 219. The average target predicts an increase of 32.95% from the current stock price of 123.29.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NBIX stock from 24 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 8 | 8 | 8 |
| Buy | 10 | 10 | 11 | 11 | 11 | 11 |
| Hold | 6 | 6 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 23 | 24 | 24 | 24 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $190 | Strong Buy | Reiterates | $190 | +54.11% | Nov 1, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Oct 31, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Oct 30, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Oct 29, 2024 |
Financial Forecast
Revenue This Year
2.40B
from 1.89B
Increased by 26.97%
Revenue Next Year
2.80B
from 2.40B
Increased by 16.69%
EPS This Year
4.10
from 2.47
Increased by 65.88%
EPS Next Year
6.28
from 4.10
Increased by 53.18%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.5B | 3.1B | 3.7B | ||
| Avg | 2.4B | 2.8B | 3.3B | ||
| Low | 2.2B | 2.5B | 2.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 32.3% | 29.9% | 32.9% | ||
| Avg | 27.0% | 16.7% | 16.9% | ||
| Low | 15.0% | 2.3% | -2.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.33 | 9.27 | 12.33 | ||
| Avg | 4.10 | 6.28 | 8.90 | ||
| Low | 3.29 | 3.58 | 5.33 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 156.3% | 126.3% | 96.4% | ||
| Avg | 65.9% | 53.2% | 41.7% | ||
| Low | 33.3% | -12.7% | -15.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.